Analyst upgrades typically indicate a positive outlook for a stock. In this case, Wells Fargo's upgrade of Blueprint Medicines from Equal-Weight to Overweight suggests they believe the stock will outperform the market or its sector in the near term. This could potentially lead to an increase in the stock's price.